Richard S.E. Keefe
Professor in Psychiatry and Behavioral Sciences
Education & Training
Ph.D., New York University 1990
Ang, MS, Abdul Rashid, NA, Lam, M, Rapisarda, A, Kraus, M, Keefe, RSE, and Lee, J. "The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia. (Accepted)" Journal of clinical psychopharmacology 37.6 (December 2017): 651-656. Full Text
Blokland, GAM, Del Re, EC, Mesholam-Gately, RI, Jovicich, J, Trampush, JW, Keshavan, MS, DeLisi, LE, Walters, JTR, Turner, JA, Malhotra, AK, Lencz, T, Shenton, ME, Voineskos, AN, Rujescu, D, Giegling, I, Kahn, RS, Roffman, JL, Holt, DJ, Ehrlich, S, Kikinis, Z, Dazzan, P, Murray, RM, Di Forti, M, Lee, J, Sim, K, Lam, M, Wolthusen, RPF, de Zwarte, SMC, Walton, E, Cosgrove, D, Kelly, S, Maleki, N, Osiecki, L, Picchioni, MM, Bramon, E, Russo, M, David, AS, Mondelli, V, Reinders, AATS, and Falcone, MA et al. "The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project." Schizophrenia research (October 2, 2017). Full Text
Lam, M, Wang, M, Huang, W, Eng, GK, Rapisarda, A, Kraus, M, Kang, S, Keefe, RSE, and Lee, J. "Establishing the Brief Assessment of Cognition - Short form." Journal of psychiatric research 93 (October 2017): 1-11. Full Text
Cella, M, Stahl, D, Morris, S, Keefe, RSE, Bell, MD, and Wykes, T. "Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory." Psychological medicine (September 4, 2017): 1-9. Full Text
Keefe, RSE, Davis, VG, Harvey, PD, Atkins, AS, Haig, GM, Hagino, O, Marder, S, Hilt, DC, and Umbricht, D. "Placebo Response and Practice Effects in Schizophrenia Cognition Trials." JAMA psychiatry 74.8 (August 2017): 807-814. Full Text
Xavier, RM, Pan, W, Dungan, JR, Keefe, RSE, and Vorderstrasse, A. "Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia." Schizophrenia research (July 7, 2017). Full Text
Mazhari, S, Ghafaree-Nejad, AR, Soleymani-Zade, S, and Keefe, RSE. "Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia." Asian journal of psychiatry 27 (June 2017): 12-15. Full Text
Hochberger, WC, Combs, T, Reilly, JL, Bishop, JR, Keefe, RSE, Clementz, BA, Keshavan, MS, Pearlson, GD, Tamminga, CA, Hill, SK, and Sweeney, JA. "Deviation from expected cognitive ability across psychotic disorders." Schizophrenia research (May 22, 2017). Full Text
Keefe, RSE, and Kahn, RS. "Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia." JAMA psychiatry 74.5 (May 2017): 535-536. Full Text
Vance, M, Pappadopulos, E, Keefe, R, and Kalali, A. "Conceptual issues in cultural adaptation and the role of culture in assessment of health-related quality of life in schizophrenia." Beyond Assessment of Quality of Life in Schizophrenia. January 1, 2016. 53-62. Full Text
Eum, S, Hill, SK, Rubin, LH, Carnahan, RM, Reilly, JL, Ivleva, EI, Keedy, SK, Tamminga, CA, Pearlson, GD, Clementz, BA, Gershon, ES, Keshavan, MS, Keefe, RSE, Sweeney, JA, and Bishop, JR. "Cognitive burden of anticholinergic medications in psychotic disorders." April 5, 2017. Full Text
Graham, KA, Keefe, RS, Lieberman, JA, Calikoglu, AS, Lansing, KM, and Perkins, DO. "Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia." October 2015. Full Text
Keefe, RSE, Mahableshwarkar, AR, and Olsen, CK. "Clinical evidence for improvement in cognitive dysfunction in patients with major depressive disorder (MDD) after treatment with vortioxetine." October 2013.
Madhoo, M, Roth, RM, Keefe, RSE, Sambunaris, A, Scheckner, B, Nielsen, J, Adeyi, B, Wu, J, and Lasser, R. "Lisdexamfetamine dimesylate augmentation effects on executive function in major depressive disorder based on depressive symptom levels." October 2012.
Madhoo, M, Keefe, RSE, Roth, RM, Sambunaris, A, Wu, J, Trivedi, MH, Anderson, CS, and Lasser, R. "Efficacy and safety of lisdexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder." June 2012.
Supina, D, Endicott, J, Madhoo, M, Keefe, RSE, Trivedi, M, Wu, J, Scheckner, B, and Lasser, R. "EFFECTS OF LISDEXAMFETAMINE DIMESYLATE AUGMENTATION ON FUNCTIONAL OUTCOMES IN ADULTS WITH PARTIALLY OR FULLY REMITTED MAJOR DEPRESSIVE DISORDER." June 2012.
Jarskog, FF, Grove, RA, McEvoy, JP, Keefe, RSE, Lowy, MT, Horrigan, JP, and Peykamian, MA. "Randomized, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study of GSK239512 for Cognitive Impairment in Stable Schizophrenia Subjects on Background Antipsychotic Therapy." April 15, 2012.
Uchida, H, Sakurai, H, Bies, RR, Stroup, S, Keefe, RSE, Suzuki, T, Tsuboi, T, Mimura, M, Pollock, BG, and Mamo, DC. "DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA." April 2012.
Colijn, MA, Barbato, M, Keefe, RSE, Perkins, DO, Woods, SW, and Addington, J. "AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION." April 2012.
Keefe, RSE, Buchanan, RW, Marder, SR, Schooler, NR, Dugar, A, Zivkov, M, and Stewart, M. "CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR?." April 2012.
BI 1289.32 Phase II Clinical Trial awarded by Boehringer Ingelheim Pharmaceuticals, Inc. (Principal Investigator). 2017 to 2020
Auditory Perception and Emotion Recognition in Young People at Risk for Psychosis awarded by National Institutes of Health (Principal Investigator). 2016 to 2018
FAST- MAS Phase 2A awarded by National Institutes of Health (Co Investigator). 2013 to 2017
Specific Auditory Perception Impairment and Emotion Recognition in Schizophrenia awarded by National Institutes of Health (Principal Investigator). 2014 to 2017
FAST- MAS Administrative Task Year 3 awarded by National Institutes of Health (Co Investigator). 2014 to 2015
IPA - Richard Keefe awarded by Durham Veterans Affairs Medical Center (Research Associate). 2013 to 2014
IPA - Richard Keefe awarded by Veterans Administration Medical Center (Research Associate). 2012 to 2013
IPA - Richard Keefe awarded by Veterans Administration Medical Center (Fellow). 2010 to 2011
Neural Circuitry And Cognitive Function In Schizophrenia awarded by National Institutes of Health (Principal Investigator). 1995 to 2001
Neural Circuitry & Cognitive Function In Schizophrenia awarded by National Institutes of Health (Principal Investigator). 1995 to 1999